Mechanisms of action of immunomodulatory drugs — from teratogenicity to treatment of multiple myeloma

Author:

Semochkin S. V.1ORCID

Affiliation:

1. Hertsen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation; Pirogov Russian National Research Medical University

Abstract

Introduction. Immunomodulatory drugs (IMiDs) are a class of chemical derivatives of thalidomide with numerous immunomodulatory, antiangiogenic, anti-inflammatory, and cytostatic effects in multiple myeloma (MM).Aim — to highlight the history of the discovery of IMiDs and discuss the molecular mechanisms of their therapeutic activity.Basic information. In 2010, more than half a century after the German company Chemie Grünenthal began the clinical use of thalidomide, the first understanding of the molecular mechanism of thalidomide and its structural derivatives appeared. Hiroshi Handa and colleagues from the Tokyo Medical University discovered that the drug thalidomide binds to the protein Cereblon (CRBN), a substrate receptor of the CRL4CRBN E3 ubiquitin ligase. Subsequent generations of immunomodulatory drugs (IMiDs) — lenalidomide and pomalidomide, are structurally like thalidomide. The glutarimide ring of IMiDs is inserted into the receptor pocket of the CRBN. In this case, the variable phthalimide part of the drug protrudes from the binding domain, changing the configuration of the CRBN in such a way that it allows it to interact with proteins (neosubstrates) with which it does not react under physiological conditions. It was later found that ubiquitin-mediated degradation of two transcription factors (Ikaros and Aiolos) underlies the antitumor and immunomodulatory activity of IMiDs, which have shown unique clinical efficacy in the treatment of multiple myeloma. A natural continuation of the success of IMiDs was the creation of a series of therapeutic molecules (Iberdomide, etc.) belonging to a new class of drugs called CELMoDs (Cereblon E3 Ligase Modulating Drugs). The presented literature review is devoted to the history of the discovery of IMiDs and a discussion of the molecular mechanisms of their therapeutic activity.

Publisher

National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation

Subject

Hematology

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3